Whole exome sequencing identifies a novel FANCD2 gene splice site mutation associated with disease progression in chronic myeloid leukemia: Implication in targeted therapy of advanced phase CML Page No: 1419-1426

By: Muhammad Absar, Amer Mahmood, Tanveer Akhtar, Sulman Basit, Khushnooda Ramzan, Abid Jameel, Sibtain Afzal, Anhar Ullah, Kulsoom Qureshi, Nawaf Alanazi, Zafar Iqbal

Keywords: CML, progression, DNA repair genes, FANCD2, PARP inhibitors, combination therapy

DOI : 10.36721/PJPS.2020.33.3.SP.1419-1426.1

Abstract: Tyrosine Kinase Inhibitors (TKIs) have significantly improved the clinical outcome of BCR-ABL+ Chronic Phase-Chronic Myeloid Leukemia (CP-CML).



[View Complete Article]